Compounded Semaglutide vs. Ozempic: What's Actually Different

Ozempic and “compounded semaglutide” get discussed as if they're interchangeable — two paths to the same drug, one just cheaper. That's not quite accurate. They can differ in the exact form of the active ingredient, how they're manufactured and reviewed, how they're dosed, and, as of 2026, whether preparing them is even legally straightforward. Here's a clear breakdown.

What "Compounded Semaglutide" Actually Is

Ozempic and Wegovy, both made by Novo Nordisk, use semaglutide in its free base form, manufactured under FDA-reviewed conditions and delivered through a pre-filled, pre-calibrated injector pen with established sterility and stability data behind it.

Compounded semaglutide is prepared differently: a licensed pharmacy (typically a 503A compounding pharmacy, sometimes a 503B outsourcing facility) mixes semaglutide active pharmaceutical ingredient into a custom vial, which a patient then draws up with a syringe rather than using a pre-set pen. During the 2023–2024 shortage, some compounders used semaglutide salt forms — sodium or acetate — instead of the free base used in the approved drugs. The FDA has been explicit that these salt forms are different active ingredients than what's in Ozempic and Wegovy, aren't the subject of any approved application, and don't have the same safety and effectiveness data behind them.

The Current Legal Picture (This Changed Recently)

This is the part that's most likely to be out of date if you're reading an older article: semaglutide came off the FDA's official drug shortage list in February 2025. That matters because large-scale compounding of a drug is only broadly permitted while it's in shortage. Once the enforcement-discretion window closed in May 2025, the rules tightened substantially.

As of 2026, a 503A pharmacy can still compound semaglutide for an individual patient, but only when a prescriber documents a genuine clinical reason the FDA-approved product won't work — a documented allergy to a specific inactive ingredient, for example, or a need for a strength or form that isn't commercially available. Cost alone isn't a recognized justification. Large 503B outsourcing facilities generally can't compound semaglutide at all right now, since it's not on the FDA's approved bulk drug substances list for that category. A federal court sided with the FDA on this in a May 2025 ruling, and the agency has since proposed making the restriction on 503B compounding permanent. If a pharmacy or telehealth provider is offering compounded semaglutide without asking about a specific clinical justification, that's worth a second look.

Safety Concerns the FDA Has Flagged

The FDA has published specific concerns about compounded semaglutide, separate from the legal-status question. Because compounded versions are typically drawn from a multi-dose vial with a syringe rather than a pre-calibrated pen, dosing errors have been reported — both patients and, in some cases, providers miscalculating doses or accelerating a titration schedule faster than the drug's studied dosing pattern. As of late 2024, the FDA had logged several hundred adverse event reports tied to compounded semaglutide, including gastrointestinal symptoms and some hospitalizations. Because compounded drugs skip the FDA's premarket review process, the agency also can't independently verify ingredient purity, potency, or sterility the way it can for an approved product — and it has separately warned about counterfeit semaglutide entering the supply chain through unauthorized sellers.

When a Compounded Version Might Still Make Sense

None of this means compounded medications are inherently unsafe when prepared properly, or that there's never a legitimate reason to use one. FDA's own compounding guidance recognizes real clinical scenarios — a documented allergy to an inactive ingredient in the brand-name product, or a patient who genuinely can't use the pen device and needs an alternate form. The distinction that matters is whether a licensed clinician is making that call based on your actual medical history, working with a pharmacy that's compounding within current legal bounds, versus a lower price being the whole rationale.

That's the standard any Motion protocol is built to meet: your clinician evaluates whether the FDA-approved product is right for you first, and any compounded alternative is only considered when there's a real, documented reason for it — not because it's cheaper.